T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

Metastatic renal cell carcinoma (RCC) has a poor prognosis. Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies. As only a subset of RCC patients respond, alternative strategies should be explored. Patients refractory to anti-PD-1 thera...

Full description

Bibliographic Details
Main Authors: Saskia D. van Asten, Rosa de Groot, Marleen M. van Loenen, Suzanne M. Castenmiller, Jeroen de Jong, Kim Monkhorst, John B.A.G. Haanen, Derk Amsen, Axel Bex, Robbert M. Spaapen, Monika C. Wolkers
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
rcc
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1860482